Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02340520 · ClinicalTrials.gov registry record · Phase 3
Enhancement of Corticosteroid Efficacy in COPD
A Phase 3 study, sponsored by UConn Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT02340520 is a Phase 3 study that has completed, run by UConn Health. The registered enrollment target is 13 participants.
The verdict
NCT02340520, a Phase 3 study, has completed, sponsored by UConn Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
This is a pilot study designed to evaluate the effects of theophylline and roflumilast on circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive to bronchodilators. Subjects will receive theophylline tablets for 1 week, followed by measurement of circulating HDAC and the acute effect of oral prednisone on the bronchodilator response to inhaled beta agonist. Roflumilast tablets will be added to the theophylline for a further week and the studies repeated. The study will provide preliminary data on the effects of theophylline and roflumilast on circulating HDAC levels and the effects of corticosteroids on the beta agonist bronchodilator response in COPD.
Interventions
- DRUG Theophylline
- DRUG Roflumilast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02340520
The ClinicalTrials.gov registry entry for NCT02340520 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UConn Health, which has 178 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Theophylline is the first listed.
NCT02340520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02340520 about?
NCT02340520 is a clinical study titled "Enhancement of Corticosteroid Efficacy in COPD". This is a pilot study designed to evaluate the effects of theophylline and roflumilast on circulating Histone deacetylase (HDAC) levels in subjects with COPD, and the bronchodilator effects of corticosteroids. Studies will be performed in 10 subjects with COPD nonresponsive to bronchodilators. Subje...
What is the current status of trial NCT02340520?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2014-12. Estimated completion is 2016-08.
What interventions are being tested in trial NCT02340520?
The interventions under investigation include: Theophylline (DRUG), Roflumilast (DRUG).
Who is sponsoring clinical trial NCT02340520?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.